Licensing
🇪🇺 EMAEMA news and analysis for pharmaceutical BD, investment, and market access
Unlock global pharma market opportunities. Get expert insights on drug licensing deals, IP strategies, and M&A trends for strategic BD.
Showing 1–12 of 13 articles
Quick answer
NovaPharmaNews Licensing hub for EMA covers 13 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
EU Pharma Package exclusivity timelines: what innovators can do now
China Becomes Big Pharma's Essential R&D Partner
MFN Drug Pricing Reshapes International Life Sciences Licensing Deals
Owkin and AstraZeneca Enhance AI Collaboration for Drug Research
European Navenibart Deal: A Strategic Win for BioCryst's Rare Disease Portfolio
SERB Pharmaceuticals Acquires European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma AB
Viridian Partners with WuXi Bio for Eye Drug Supply Amid FDA Decision
Roche's Licensing Deal for Xofluza: Implications and Insights
Gilead's $140M Deal with Yuhan: Implications for Pharma
BioCryst Secures $70M Upfront in European Licensing Deal for Navenibart Hereditary Angioedema Treatment
Pharma 2026: Key Takeaways from EU Biopharma & Medtech
Reuters Pharma EU: Funding & Dealmaking Key Takeaways
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.